Acorda Therapeutics (DB:CDG) - Prezzo delle azioni, notizie e analisi

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CDG Panoramica delle azioni

A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Maggiori dettagli

CDG analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	3/6
Dividendi	0/6

Premi

Gli utili sono cresciuti del 10.3% all'anno negli ultimi 5 anni

Analisi del rischio

Le azioni sono altamente illiquide

Non ha una capitalizzazione di mercato significativa ( €15M )

Gli azionisti sono stati diluiti nell'ultimo anno

Acorda Therapeutics, Inc. Concorrenti

Medigene

XTRA:MDG1

€22.6m

co.don

XTRA:CNW

€6.5m

Paion

XTRA:PA8

€2.6m

Heidelberg Pharma

XTRA:HPHA

€103.9m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Acorda Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$8.42
Massimo di 52 settimane	US$21.80
Minimo di 52 settimane	US$5.64
Beta	1.43
1Variazione di 1 mese	0%
Variazione a 3 mesi	-6.83%
Variazione di 1 anno	10.25%
3Variazione a 3 anni	-83.90%
Variazione a 5 anni	-99.70%
Variazione dall'IPO	-98.76%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	CDG	DE Biotechs	DE Mercato
7D	0%	-0.7%	-0.02%
1Y	10.2%	-17.2%	8.2%

Ritorno vs Industria: CDG ha superato il German Biotechs che ha restituito -17.2 % nell'ultimo anno.

Rendimento vs Mercato: CDG ha superato il mercato German che ha restituito 8.2 % nell'ultimo anno.

Volatilità dei prezzi

Is CDG's price volatile compared to industry and market?
CDG volatility
CDG Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di CDG è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di CDG nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1995	111	Ron Cohen	www.acorda.com

Acorda Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Acorda Therapeutics con la sua capitalizzazione di mercato?
CDG statistiche fondamentali
Capitalizzazione di mercato	€14.12m
Guadagni(TTM)	-€19.42m
Ricavi(TTM)	€108.53m

0.1x

Rapporto P/S

-0.7x

Rapporto P/E

CDG è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CDG Conto economico (TTM)
Ricavi	US$116.91m
Costo del fatturato	US$27.38m
Profitto lordo	US$89.53m
Altre spese	US$110.45m
Guadagni	-US$20.92m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-16.84
Margine lordo	76.58%
Margine di profitto netto	-17.89%
Rapporto debito/patrimonio netto	259.6%

Come si è comportato CDG nel lungo periodo?

Vedi performance storica e confronto

This company listing is no longer active

CDG Panoramica delle azioni

Premi

Analisi del rischio

Acorda Therapeutics, Inc. Concorrenti

XTRA:MDG1

€22.6m

XTRA:CNW

€6.5m

XTRA:PA8

€2.6m

XTRA:HPHA

€103.9m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Motion for Joint Administration Filed by Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings released: US$1.93 loss per share (vs US$3.53 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Revenue beats expectations

Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)

Acorda Therapeutics Announces Executive Changes

Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index

Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million.

New 90-day high: €5.42

Third quarter 2020 earnings released: EPS US$0.15

Revenue beats expectations

New 90-day high: €0.89

Acorda Therapeutics, Inc. to Report Q3, 2020 Results on Nov 03, 2020

Steven M. Rauscher to Resign as Member of Board of Directors of Acorda Therapeutics, Inc

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI Index

New 90-day low - €0.40